A 24-week Randomised Exploratory Open-Label Study Aiming To Characterise Changes In Airway Inflammation, Symptoms, Lung Function, And Reliever Use In Asthma Patients Using SABA (Salbutamol) Or Anti-Inflammatory Reliever (SYMBICORT®) As Rescue Medication In Addition To SYMBICORT As Daily Asthma Controller
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Budesonide/formoterol (Primary) ; Salbutamol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms STIFLE
- Sponsors AstraZeneca
Most Recent Events
- 17 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2022 Planned End Date changed from 30 Sep 2022 to 19 Jan 2023.